Inflammatix, Inc., based in Sunnyvale, California, USA, is revolutionizing molecular diagnostics with machine-learning-powered technology to rapidly read a patient’s immune response to improve patient care and reduce major public health burdens. It’s flagship in vitro diagnostic (IVD) test, the TriVerity™ Test System (“TriVerity”) shows the likelihood of a bacterial infection, a viral infection, and illness severity in adult patients with suspected acute infection or sepsis that present to emergency departments. TriVerity empowers physicians to confidently make care decisions, which could influence the selection of antimicrobial therapy, focused workups with judicious laboratory and imaging orders, and patient admission or discharge disposition. TriVerity and future tests are designed to be performed on the company’s proprietary Myrna™ instrument, a cartridge-based benchtop analyzer that is capable of multiplex sample-to-answer quantitation of mRNA in about 30 minutes.
External link for Inflammatix, Inc.
540 Oakmead Pkwy
Sunnyvale, California 94085, US
Attending #AAEM25? Join #TeamInflammatix on April 8th at our New Technology Luncheon! CEO Tim Sweeney, MD, PHD and CMO Sam Ajizian MD, will lead a deep dive into TriVerity™, the only FDA-cleared blood test as an aid in the diagnosis of acute infection and prognosis for sepsis. Space is limited, so the event is first-come, first-serve. See you there! #EmergencyMedicine #HealthcareInnovation #Diagnostics #Sepsis
This content isn’t available here
Access this content and more in the LinkedIn app
Join #TeamInflammatix Wednesday, April 16th [register here: https://lnkd.in/geQXXucs] for an in-depth webinar on the TriVerity™ Test System, led by Chief Medical Officer Sam Ajizian MD. Dr. Ajizian will cover: - An overview of the TriVerity™ Test System and Myrna Instrument - The impact of rapid sepsis detection on both hospitals and patients - Case studies and expert insights delving into the needs met by advanced diagnostics Can’t attend Wednesday? We’re offering a second session on Thursday, April 17th. Register here: https://lnkd.in/geQXXucs #EmergencyMedicine #HealthcareInnovation #Diagnostics #Sepsis #HealthcareWebinar
This content isn’t available here
Access this content and more in the LinkedIn app
It is an esteemed privilege to announce that we’ve signed a contract with the U.S. Military’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND to bring our TriVerity™ Test System to the field. This exciting partnership opens up major opportunities to impact patient care on a national scale with rapid infection diagnosis, leading to swifter, more informed patient disposition decisions. “TriVerity’s ability to rapidly rule in and rule out bacterial infection, viral infection and illness severity has the potential to streamline triage for our Armed Forces in forward environments," said Dr. Tim Sweeney, CEO and co-founder of Inflammatix, Inc. “We are pleased that the JPEO-CBRND has chosen to evaluate our TriVerity Test System, including TriVerity cartridges and the Myrna instrument, for military use." Read more in today’s release: https://lnkd.in/eMaZrCp8 #HealthcareInnovation #Diagnostics #Sepsis #EmergencyMedicine
8 years in the making – and just 2 months after FDA clearance – and the big moment is finally here! The first-ever commercial shipment of the TriVerity test system, which includes TriVerity Cartridges and the Myrna Instrument, left our HQ and got delivered to our first customer! This groundbreaking milestone would not be possible without the incredible years of dedication and meticulous work from so many on #TeamInflammatix. Now, the next phase of our work truly begins – to transform emergency medicine and improve patient care through advanced interpretation of the immune response. With #TriVerity, we’re ushering in a paradigm shift in rapid infection diagnosis and health system resource management. The journey ahead is incredibly exciting, and we can’t wait for the profound difference we’ll make together! #EmergencyMedicine #HostResponse #Diagnostics #InfectionManagement #Sepsis #EmergencyMed #IVD #HealthcareInnovation #HealthcareTransformation #PatientCare
Inflammatix, Inc. reposted this
Traditional diagnostic methods take hours—time that critically ill patients don’t have. What if we could decode the immune system’s response through gene expression—before any traditional test results came back? Inflammatix, Inc. is making this a reality and QIAGEN Genomic Services were proud to support this breakthrough, providing the genomic expertise and tools needed to bring their vision to life. As part of this process, the use of PreAnalytiX PAXgene Blood RNA Tubes — a joint venture between QIAGEN and BD — ensured high-quality RNA stabilization for accurate gene expression analysis. Innovative breakthroughs need the right support—and we’re excited to be part of this story. Watch how it all comes together.
Our Co-Founder and Chief Scientist Purvesh Khatri will participate in a panel discussion at the 32nd International Precision Med TRI-CON, in a session entitled, “Host Response Profiling in Infectious Diseases.” Advanced host-response diagnostics are transforming the way we detect infections, moving beyond traditional blunt biomarkers and pathogen-based tests to focus on how the body specifically responds to infection. This shift is critical for improving diagnosis, guiding precision treatment, and reducing antibiotic misuse. See session details here: https://lnkd.in/ec4zpCSW
It’s IHI Patient Safety Awareness Week, a time to spotlight the importance of safety in healthcare settings. Our team at Inflammatix is committed to offering the healthcare community better tools to improve patient safety in patients suspected of acute infections and sepsis. With immune host response technology, we can enable earlier detection and more precisely targeted intervention that may lead to a future with improved outcomes, including lower mortality. #PatientSafety #sepsis
Don't miss this manuscript to learn more of what Tim and Ljubomir are talking about! https://lnkd.in/etQwgB4K
Volume 259 The Proceedings of Machine Learning for Health 2024 https://lnkd.in/eAKeg9Bi Is now available on PMLR.
This editor’s choice study in Critical Care Medicine, the journal of the Society of Critical Care Medicine, reinforces that sepsis treatment is not one-size-fits-all. The latest research highlights the wide variability in treatment response among sepsis patients - underscoring the urgent need for precision medicine in critical care. We have been at the forefront of #sepsis subtypes (or ‘endotypes’) research. By leveraging gene expression, we aim to move beyond blanket treatment approaches, with the goal of guiding clinicians to the right treatment for the right patient at the right time. Learn more at https://lnkd.in/e_USuUyP Read the study: https://lnkd.in/d4-fiaN4 #PrecisionMedicine
Attending the Society of Critical Care Medicine Critical Care Congress, February 23-25, 2025 in Orlando, FL? Our CEO and Co-Founder Tim Sweeney will deliver an oral presentation on TriVerity, our FDA-cleared molecular blood test for adult emergency department patients suspected of acute infection or sepsis #SCCM2025. Check out this Research Snapshot Theater session to learn more. You can register here https://lnkd.in/dcPuPZmq